Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 1,457 shares, a growth of 762.1% from the April 30th total of 169 shares. Based on an average trading volume of 4,944 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the company’s shares are short sold.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PBE. Colonial Trust Advisors acquired a new position in Invesco Biotechnology & Genome ETF in the fourth quarter valued at approximately $25,000. Fifth Third Bancorp acquired a new position in Invesco Biotechnology & Genome ETF in the first quarter valued at approximately $30,000. Comerica Bank lifted its holdings in Invesco Biotechnology & Genome ETF by 86.2% in the fourth quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after acquiring an additional 175 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Invesco Biotechnology & Genome ETF by 74.5% in the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after acquiring an additional 245 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in Invesco Biotechnology & Genome ETF by 63.2% in the third quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock valued at $62,000 after acquiring an additional 342 shares during the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

PBE traded down $0.09 during trading hours on Friday, reaching $83.80. The company’s stock had a trading volume of 4,891 shares, compared to its average volume of 6,666. Invesco Biotechnology & Genome ETF has a fifty-two week low of $62.25 and a fifty-two week high of $85.73. The stock has a market cap of $260.62 million, a PE ratio of 20.44 and a beta of 0.71. The business’s 50-day moving average is $80.32 and its 200-day moving average is $80.93.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.